Two VPs leaving within weeks of each other....this is only foreshadowing major change. Anand and Anette have been with Amgen for over 10 year and at a VP level. Tony Hooper would never promote them any further. They bring a new VP of marketing with a digital health background who hasn't been in pharma in over 15 years. That's the new focus now without brodalumab. It's going to be a limited INBU field team and more focus on DTC and digital health. The writing is on the wall my friends. Get out now before the next round of layoffs!
Look at Amgen's moves, not the ambiguous comments from Daniel Billen. He's just looking to maximize financial performance from you before letting you go because his bonus depends on it. You are nothing more than a new BMW for him.
Look at Amgen's moves, not the ambiguous comments from Daniel Billen. He's just looking to maximize financial performance from you before letting you go because his bonus depends on it. You are nothing more than a new BMW for him.
Wakeup INBU! Anand Varadan and Annette Wakeford is a sign of bad things!!!
Aucun commentaire:
Enregistrer un commentaire